GSK Pharma's Q3 Profit Jumps 35% on Strong Demand for Augmentin, Respiratory Drugs
Written By : Farhat Nasim
Published On 2025-02-16 06:15 GMT | Update On 2025-02-16 06:15 GMT
Bengaluru: India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
The Indian unit of British drugmaker GSK said its profit before exceptional items and tax jumped 35per cent to 3.08 billion rupees ($35.5 million) in the October-December quarter.
The company had an exceptional charge of 1.63 billion rupees in the year-ago period due to costs related to a one-time voluntary retirement scheme.
Its revenue from operations climbed 18per cent to 9.49 billion rupees in the third quarter.
GlaxoSmithKline Pharma has been benefitting from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Strong demand for its vaccine for shingles, Shingrix, has also boosted earnings, the company said.
These have also helped it mitigate the impact of pricing curbs on some of its drugs that have been added to the Indian government's essential medicines list since September 2022.
Antibiotics and respiratory drugs are the company's biggest segments.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.